Study objective: There are limited data on the clinical presentations and management of dabigatran-associated major bleeding outside the clinical trial setting. The aim of this study is to describe clinical characteristics, interventions, and outcomes in patients with dabigatran-associated major bleeding who present to the emergency department (ED).
INTRODUCTION Background
The first decades of the 21st century have seen a significant change in the options for oral anticoagulation, with the advent of non-vitamin K oral anticoagulant agents for stroke prevention in nonvalvular atrial fibrillation, and prevention and treatment of venous thromboembolism. The non-vitamin K oral anticoagulant agents are rapidly replacing warfarin, the mainstay of oral anticoagulation for the past 50 years, prescribed 22 million times annually in the United States. 1 Warfarin has long been a leading cause of drug-related adverse bleeding events. Multiple clinical trials have established that the non-vitamin K oral anticoagulant agents are at least as efficacious as warfarin for the prevention of stroke and systemic emboli in patients with nonvalvular atrial fibrillation and for the management of venous thromboembolism. [2] [3] [4] Furthermore, the non-vitamin K oral anticoagulants have been associated with fewer major bleeding events than warfarin and tend to lead to less intracranial hemorrhage but more gastrointestinal bleeding. 4 Warfarin-related hemorrhages historically have been managed with vitamin K and fresh frozen plasma and more recently with prothrombin complex concentrates. 5, 6 Until recently, no specific reversal agents for the non-vitamin K oral anticoagulant agents have been available outside clinical trials. The first non-vitamin K oral anticoagulant agent approved for clinical use was dabigatran, a direct thrombin inhibitor. Dabigatran is most commonly Volume 69, no. 5 : May 2017
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Editor's Capsule Summary
What is already known on this topic Dabigatran-associated bleeding is poorly described.
What question this study addressed What were the major bleeding events, treatments, and outcomes in patients receiving dabigatran for nonvalvular atrial fibrillation before the era of specific antidotal therapy?
What this study adds to our knowledge Of 191 eligible patients identified retrospectively from 5 emergency departments, 62% had gastrointestinal, 19% had intracranial, and 15% had trauma-related bleeding. The most common interventions were RBC and plasma transfusions, and 6% died (75% of those deaths from gastrointestinal bleeding).
How this is relevant to clinical practice
This knowledge will be useful in guiding development of protocols for the treatment of this condition.
prescribed for the risk reduction of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. As a consequence of their age and comorbidities, these patients are also the most likely to experience bleeding complications. 7 For this reason, we focused on the population of nonvalvular atrial fibrillation patients who were receiving dabigatran to characterize a sample of anticoagulated major bleeding episodes.
Importance
The non-vitamin K oral anticoagulant agents, including dabigatran, were associated with fewer major bleeding events than warfarin in phase 3 clinical trials, 2,4 and early reports after Food and Drug Administration approval suggested that dabigatran-induced bleeding had a more benign clinical course compared with that of warfarin. 8 We sought to describe the characteristics, treatment, and outcomes of patients with major bleeding while receiving dabigatran in routine clinical practice.
Goals of This Investigation
Our goal was to assemble a multicenter cohort of nonvalvular atrial fibrillation patients with major bleeding while receiving dabigatran and characterize clinical presentations, treatment, and outcomes.
MATERIALS AND METHODS Study Design and Setting
We performed a study of nonvalvular atrial fibrillation patients who were receiving dabigatran, had an acute major bleeding event (index event), and presented to an emergency department (ED) at 5 sites in the United States. We identified subjects by electronic medical record searches cross-referencing medication lists and International Classification of Diseases, Ninth Revision (ICD-9) and ICD-10 codes for hemorrhage. We then manually reviewed the charts for patients meeting the major bleeding criteria of the International Society for Thrombosis and Haemostasis. The 5 sites obtained individual institutional review board or independent ethics committee approval from their local institutional review board to conduct the study.
The period under review was from October 19, 2010 (when dabigatran was approved for the US market), to the date of institutional review board approval and subsequent electronic medical record query, which varied by site.
Because this study abstracted anonymous data devoid of patient identifiers, all institutional review boards granted patient written informed consent waivers. One or more experienced research assistants or coordinators at each site collected the data. They were aware of the general purpose of the study but not the details. Cases were reviewed by investigators at each site and entered into an electronic case report form and finally into a central database managed by an independent contract research organization. We did not formally assess interrater reliability by reabstracting a subset of the charts. The contract research organization's medical monitor did query database entries for accuracy.
Selection of Participants
Patients were eligible for inclusion if they were aged 18 years or older, had a documented diagnosis of nonvalvular atrial fibrillation, had received a dose of dabigatran within 5 days of the index event, and presented to the hospital with a major bleeding episode (see Figure 1 for a complete list of inclusion and exclusion criteria). The International Society for Thrombosis and Haemostasis criteria defined major bleeding and included one of the following: fatal bleeding, bleeding into a major organ or critical area (eg, intracranial, retroperitoneal, pericardial, intraspinal, intra-articular, intraocular), a decrease in hemoglobin level of 20 g/L, or transfusion of at least 2 units of blood. 9 Patients receiving additional oral or parenteral anticoagulants or thrombolytics were excluded.
Data Collection and Processing
We used a standardized electronic case report form to abstract information from the medical records. We collected specific details in regard to the timing and dosing of dabigatran, as well as the estimated time since nonvalvular atrial fibrillation diagnosis. We also noted the presence of renal failure, comorbidities, and concomitant medications, and the characteristics of the index bleeding event (type and location of bleeding).
Outcome Measures
The primary outcomes were the number of patients with an index event (ongoing, resolved, or deceased) at hospital discharge or release, the proportion of patients receiving different types of interventions to manage the index event (including intravenous fluids, blood and blood products, factor concentrates, and hemodialysis), frequencies of bleeding types, and anatomic locations of the index events at ED presentation. The status "ongoing" was not clinically defined and was left to the investigators' discretion according to their review of the medical records. We also calculated total length of stay in the hospital and ICU.
Primary Data Analysis
We used descriptive statistics to summarize the study outcomes. We present binary data as the number and proportion of occurrence and continuous data as means and SDs or medians and interquartile ranges (IQR), as appropriate. We stratified outcomes according to baseline characteristics such as age and type of bleeding. We used SAS (version 9.2; SAS Institute, Inc, Cary, NC) to perform all statistical analyses.
RESULTS

Characteristics of Study Subjects
Of 284 patient charts we identified at the initial screening, 93 did not to meet the International Society for Thrombosis and Haemostasis major bleeding criteria, and we excluded them from the study, leaving 191 eligible charts. See Table 1 for enrollment by site. Gastrointestinal bleeding was the most common type of index event, occurring in 118 subjects (62%); lower gastrointestinal tract bleeding (n¼65; 34%) was more frequent than upper gastrointestinal tract bleeding (n¼43; 23%). Intracranial bleeding was the next most common type of bleeding, occurring in 36 subjects (19%), with traumatic cases (n¼28; 15%) being more common than nontraumatic ones (n¼8; 4%); of the 28 traumatic intracranial bleeding cases, 27 (14%) were associated with falls and 1 (0.5%) was related to a motor vehicle crash. The index event type was "other" (eg, epistaxis, hemoptysis, urogenital, intraspinal, intra-articular) in 36 subjects (19%); the incidence of each of these "other" bleeding events was less than 1.7%. One subject (0.5%) had an "unknown" bleeding type that was found to meet the International Society for Thrombosis and Haemostasis criteria for major bleeding. See Table 3 for a summary of index events by anatomic location and type. Intracranial bleeding accounted for a higher proportion of all bleeding events in older patients: 21% of subjects (n¼26) older than 75 years, 18% (n¼8) of those aged 65 years to younger than 75 years, and 9.5% (n¼2) of those younger than 65 years.
Main Results
Treating physicians used intravenous fluid most commonly to manage the index event in the cohort, administered in 139 subjects (73%), with a mean 1,219 mL (SD 2,070 mL). Blood transfusion was the second most commonly used intervention. Clinicians used transfusion of packed RBCs to manage the index event in 99 subjects (52%) (with a mean of 1,073 mL administered [SD 661 mL]) while using whole RBC transfusion in 10 subjects (5%).
Clinicians used fresh frozen plasma in 47 subjects (25%), with a mean 1,297 mL (SD 952 mL) administered. They less commonly used plasma cryoprecipitate and platelets, in only 3 (2%) and 11 (6%) subjects, respectively. Coagulation factor concentrates were given rarely (to only 11 subjects [6%]); 5 subjects (3%) received recombinant factor VIIa, 6 (3%) were given 3-factor prothrombin complex concentrate, and 1 (0.5%) was given 4-factor prothrombin complex concentrate (1 subject received 2 factor concentrates, which is the reason the total number of subjects receiving factor concentrates is 11 and not 12). None of the patients receiving factor products died, and length of stay was short (2 to 3 days), but the small numbers do not allow statistical comparisons.
Seven patients received vitamin K (4%). Only 1 patient (0.5%) underwent hemodialysis. See Table 4 for summary data.
At presentation, 138 subjects (72%) were receiving dabigatran 150 mg twice daily and 41 (22%) subjects were receiving dabigatran 75 mg twice daily; the dabigatran dosage was unknown in 12 subjects (6%). The mean duration of dabigatran exposure at presentation (in the 113 patients for whom it was available) was 233 days (SD 243 days).
Overall, a higher proportion of subjects receiving dabigatran 150 mg twice daily (high dose) received blood transfusions, as well as a higher volume of blood transfusions, compared with the subjects receiving 75 mg twice daily (low dose). A similar pattern was observed for other transfusions, although a notable divergence was observed with fresh frozen plasma and fluids; a greater percentage of the high-dose group received these transfusions but a greater volume of these was used in the low-dose patients. Table 5 provides a summary of the use of transfusions and infusions. The mean hospital length of stay was 7 days (SD 6 days; n¼190), median was 5 days (IQR 3 to 8 days). In 145 (76%) of the subjects, the length of hospital stay was less than or equal to 10 days, whereas it was 11 to 20 days and 21 to 30 days for 21 (11%) and 6 (3%) subjects, respectively. The length of stay was reported as greater than 100 days for 1 subject (0.5%). Mean ICU length of stay was 5 days (SD 7 days; n¼77); median was 3 days (IQR 1 to 5 days).
Approximately 17% of the subjects (n¼32) had had a previous bleeding event at presentation. The most common types of previous bleeding events were gastrointestinal (n¼16; 8.4%), urogenital (n¼4; 2.1%), and intracranial (n¼3; 1.6%).
Renal function testing was performed for 181 of the patients (94.8%) at presentation, and their mean creatinine clearance was 58.9 mL/minute (SD 29.95 mL/minute) (Cockroft-Gault method).
Seventy-five of the subjects (39%) were receiving concomitant antiplatelet medications. Of these subjects, data were not reported for 7. Overall, 68 subjects who were receiving concomitant antiplatelet therapy had a median length of stay of 5.5 days (IQR 4 to 8 days); the mean length of stay was 7.2 days (SD 5.52 days). Of the 68 subjects in the hospital, 32 were in ICU for a median of 3.5 days (IQR 2 to 6 days); the mean was 5 days (SD 5 days). Six subjects (9%) died. Outcomes were similar whether patients were receiving aspirin or clopidogrel (data not shown).
LIMITATIONS
Because this was a study based on chart review, the quality and extent of the data obtained were dependent on the quality and accuracy of routine documentation. A lack of documented medical intervention or procedure does not necessarily mean it did not occur, and any incomplete information in the records could also be because of the possibility that part of the usual care was provided at a different medical center before transfer to the participating center, and we might not have captured this in all cases. There were undoubtedly bleeding cases in the communities that were not treated in participating EDs or were treated in other settings, and some patients may have died before reaching the hospital.
The data abstractors were trained research assistants and coordinators at the sites, accessing an electronic medical record and completing electronic case report forms, and no attempts were made to assess interrater reliability. The data coordinating center's medical monitor queried inconsistent or unusual findings.
The algorithmic approach using ICD-9 or ICD-10 codes suffers from the well-described limitations of using an administrative database for clinical research. 11 Furthermore, the assessment of the effect of interventions was subject to confounding by indication; that is, the most intensive treatments were likely given to patients with the most severe disease. There is also the possibility that certain information was selectively reported in the medical charts. Generalizability is limited because only 5 study sites were included.
The small sample size renders additional analyses by bleeding location or type unfeasible. We did not collect data on a control group, such as nonanticoagulated bleeding patients or patients bleeding while receiving other anticoagulants. We decided to focus our resources on collecting as much data on dabigatran-related bleeding scenarios as possible because less is known about these outside of clinical trials.
The inclusion criterion was at least 1 dose of dabigatran in the 5 days preceding the bleeding presentation, so some patients might not have received anticoagulation. However, if clinicians documented dabigatran in the setting of hemorrhage, it is likely they believed it had some role in the clinical setting. 
DISCUSSION
Patients in this cohort appeared to have relatively good clinical outcomes despite limited interventions. These results are in agreement with those of previously published studies. [2] [3] [4] Investigators have described the characteristics, treatment, and outcomes of patients with major hemorrhage while receiving dabigatran and of controls in clinical trials (5 randomized trials in atrial fibrillation and venous thromboembolism). [2] [3] [4] A major finding in the combined analysis of the 5 trials, which was conducted by Majeed et al, 4 was that dabigatran patients required more RBC transfusions and warfarin patients received more plasma. Patients receiving dabigatran also had a shorter stay in the ICU and a trend toward lower mortality. A somewhat surprising finding in study by Majeed et al 4 was how little appeared to have been done to reverse the effects of either drug, despite guidelines at the time recommending vitamin K, plasma, and various coagulation factor products for warfarin reversal in major hemorrhage 12 and RE-LY trial steering committee guidance for similar approaches to bleeding dabigatran patients not responding to supportive care. 4 Some postmarketing work has been published on bleeding complications of dabigatran versus warfarin. For example, Berger et al 8 found that dabigatran-induced hemorrhages had a more benign course and resulted in a shorter hospital length of stay than similar warfarininduced bleeding episodes. Mortality of dabigatranassociated hemorrhage was similar in our data set, 6% versus 9% (compared with 13% for warfarin) in the pooled clinical trial data, 4 although lower than observed in the data set of Berger et al, 8 which found 12% mortality (compared with 13% for warfarin). 8 Also similar between our study and that by Majeed et al 4 was the relative rarity of factor product (activated prothrombin complex concentrate, 3-and 4-factor nonactivated prothrombin complex concentrate, and recombinant factor VIIa) administration for anticoagulant reversal, at 6% compared with 2% for dabigatran and 3% for warfarin in clinical trials. The evidence for factor product use in non-vitamin K oral anticoagulant reversal is sparse (although not for warfarin reversal when the evidence is compelling 5, 6 ) and largely based on 2 randomized trials in nonbleeding healthy normal volunteers (a total of 22 subjects) with somewhat conflicting results. 13, 14 A specific, rapid, and effective reversal agent for dabigatran, the monoclonal antibody antigen-binding fragment idarucizumab, was Food and Drug Administration approved for use in the United States on October 16, 2015, for emergency surgery or urgent procedures or in life-threatening or uncontrolled bleeding. 15 Pollack et al 15 recently reported data for the first 90 patients in the RE-VERSE AD study, which includes lifethreatening bleeding or need for emergency surgical intervention as 2 separate groups. The interim report concluded that idarucizumab completely reversed the anticoagulant effect of dabigatran in 88% to 98% of the patients at the conclusion of intravenous administration. There were 18 deaths overall, with 9 in each group, although underlying severity of medical condition was not an exclusion criterion in the trial. The major hemorrhage cohort of RE-VERSE AD reported 9 deaths out of 51 patients, for a mortality rate of 18%. In this study, the mortality rate was 6%. RE-VERSE AD had 35% intracranial hemorrhages compared with 19% in this study. The mortality rates may not be directly comparable because of the differences in the study design, patient population, and type of major bleeding events between these 2 studies.
Hemodialysis, a reversal method for dabigatran with pharmacokinetic and pharmacodynamic mechanistic and clinical evidence, 16 was performed for only 1 patient in our data set (and 1 in the analysis by Majeed 4 ). This may reflect the difficulty of arranging and managing dialysis in these life-threatening presentations.
In regard to other interventions in our cohort, treating physicians used fluid administration most frequently to manage the index event (n¼139; 73%). Fluid use was not reported on clinical trial patients. Clinicians gave blood transfusion (whole blood or packed RBCs) second most commonly (n¼109; 57%), using plasma in 47 subjects (25%) and platelet transfusions to 11 (6%). In the clinical trial data, 59% of dabigatran patients received RBCs, 20% received plasma, and 4% received platelets. 4 It is difficult to determine from the data of Majeed et al 4 or ours whether plasma was being used as a volume expander or a "reversal" agent for dabigatran, the former of which might be clinically reasonable but the latter of questionable utility. Plasma would not be expected to contain factor IIa levels sufficient to have an effect on dabigatran-mediated anticoagulation. 17 Similarly the 7 patients (4%) in our study (and 10% in the analysis by Majeed et al 4 ) who received vitamin K either represent clinician confusion with warfarin because it would be unlikely to affect dabigatran, which directly binds thrombin (factor IIa) and does not affect vitamin K, or attempted reversal of a concomitant coagulopathy such as from nutritional deficiency. Cryoprecipitate (n¼3; 2%) and plasma expanders (n¼2; 1%) also were rarely used in our cohort, as they were in that of Majeed et al. 4 Our cohort highlights the various approaches to management and attempted reversal of dabigatran-induced bleeding that may be standardized and simplified now that idarucizumab is approved.
The median length of stay in the hospital was 5 days compared with 8 days in study by Majeed et al. 4 For 76% of our subjects, the hospital length of stay was less than or equal to 10 days, whereas it was 11 to 20 days and 21 to 30 days for 21 (11%) and 6 (3%) subjects, respectively. Median ICU length of stay was 3 days in our data. ICU length of stay in the study by Majeed et al 4 was reported as 1.6 days for dabigatran. Our data offer an actual comparison to the combined clinical trial data in the study by Majeed et al. 4 There were 32 subjects (17%) in our sample who had previous bleeding events and who thus had an increased risk of a recurrence. Furthermore, 75 subjects (39%) were receiving concomitant medications, such as clopidogrel and aspirin, that are known to increase bleeding risk of patients receiving dabigatran. 18 We enrolled approximately 44% of eligible patients at an 11-hospital network in central Texas (Seton Dell Medical School). The remaining 56% were from 4 Northeast US hospitals (Long Island, Brooklyn, and Boston [2 hospitals]). This allows some geographic diversity in the sample, and the number of sites increases external validity.
Overall, for patients with major bleeding events, outcomes in this study were consistent with those observed in clinical trials and subsequent combined analyses. A majority of the index events in this study cohort were treated successfully with conventional strategies.
